Atomic AI is a South San Francisco biotechnology company fusing machine learning with structural biology to unlock RNA drug discovery. Its platform pairs in-house wet-lab chemical-mapping data with deep learning models - including ATOM-1, a foundation model for RNA structure, and PARSE, its RNA structure exploration platform - to find structured, ligandable RNA motifs and design selective small molecules and RNA-based medicines for targets long considered undruggable.
Richard Yu is the Co-founder and CEO of Abalone Bio, an Emeryville, California-based biotechnology company pioneering AI-guided antibody drug discovery for notoriously hard-to-drug targets. With a PhD in Molecular Biophysics from Yale and a background spanning structural biology, systems biology, and biotech entrepreneurship, Richard built Abalone Bio's FAST platform - a high-throughput yeast cell screening system capable of evaluating 100 million antibody variants simultaneously. The company has secured partnerships with Pfizer and Mount Sinai, generated $7M in non-dilutive NIH grants, and published the world's first CB2 antibody agonist data, while positioning AI and large-scale functional datasets at the core of next-generation antibody therapeutics.
Thomas J. Cahill, MD, PhD is the founder and managing partner of Newpath Partners, a Boston-based life sciences venture firm he built from the ground up to translate breakthrough academic science into medicines. A structural biologist trained under two Nobel laureates, Cahill has co-founded more than a dozen biotech companies — including Prime Medicine, Chroma Medicine, and Autobahn Therapeutics — and became one of the pandemic's most consequential behind-the-scenes operators when he assembled Scientists to Stop COVID-19, a coalition that fed curated research directly to the White House and helped redirect Regeneron's manufacturing to Dublin.